The search for the ideal SERM

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 6, 2002, Pages 681-691

  Arun, Banu ^a   Anthony, Marietta ^a   Dunn, Barbara ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Cardiovascular; Cognitive function; Hormone replacement therapy; Hot flush; Oestrogen; Osteoporosis; Selective oestrogen receptor modulator

Indexed keywords

ALENDRONIC ACID; CALCIUM; CONJUGATED ESTROGEN; DROLOXOFENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; IDOXEFENE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR 3; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TISSUE SPECIFICITY; ANIMAL; CARDIOVASCULAR DISEASE; COGNITION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; NEOPLASM; POSTMENOPAUSE;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COGNITION; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPOROSIS; POSTMENOPAUSE; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0036079194     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.6.681     Document Type: Review

References (138)

1. Estrogen and the risk of breast cancer
2. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
3. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
4. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
5. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from epidemiological 51 studies of 52,705 women with breast cancer and 108,411 women without breast cancer
6. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
7. The pharmacology and clinical uses of tamoxifen
8. Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells
9. Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cells
10. Chemoprevention of breast cancer with tamoxifen
11. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
12. Antitumor activity of the antiestrogen ICI 46,474 (tamoxifen) in the dimethylbenzantracene (DMBA)-induced rat mammary carcinoma model
13. Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model
14. Pharmacology of tamoxifen in laboratory animals
15. Anti-oestrogenic and anti-tumor properties of prolonged tamoxifen therapy in C3H/OUJ mice
16. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications
17. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
18. Potential role of tamoxifen in prevention of breast cancer
19. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
20. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial
21. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
22. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer
23. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
24. Tamoxifen for early breast cancer: An overview of the randomised trials
25. Progress in breast cancer chemoprevention
26. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
27. Chemoprevention of mammary carcinogenesis in the rat: Combined use of raloxifene and 9-cis-retinoic acid
28. Phase II evaluation of Ly156758 in metastatic breast cancer
29. Effects of high dose raloxifene in selected patients with advanced breast carcinoma
30. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
31. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
32. Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants
33. Incident primary breast cancers are reduced by raloxifene: Integrated data from multicenter double blind, randomized trials in - 12,000 postmenopausal women
34. Breast cancer prevention: Results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT)
35. Phase I trial of droloxifene in patients with metastatic breast cancer
36. Droloxifene, a new antiestrogen: Its role in metastatic breast cancer
37. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
38. Clinical potential of new antiestrogens
39. Phase I study of a third-generation selective estrogen receptor modulator, LY353381. HCL, in metastatic breast cancer
40. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy
41. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
42. Endometrial cancer in tamoxifen treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP)
43. Risk of endometrial cancer after tamoxifen treatment of breast cancer
44. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies
45. Side effects of adjuvant treatment of breast cancer
46. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial
47. The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients
48. The precursors of endometrial carcinoma
49. Molecular determinants for the tissue specificity of SERMs
50. IARC on tamoxifen
51. Tamoxifen and risk of large bowel cancer in women with breast cancer
52. Colorectal cancer following tamoxifen therapy for breast cancer (United States)
53. A unitary model for involutional osteoporosis: Estrogen deficiency causes both Type I and Type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
54. Endogenous hormones and the risk of hip and vertebral fractures among older women
55. Treatment of postmenopausal osteoporosis with transdermal estrogen
56. Drugs for prevention and treatment of postmenopausal osteoporosis
57. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS)
58. NIH Consensus conference. Optimal calcium intake
59. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
60. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
61. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
62. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
63. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
64. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
65. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
66. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
67. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
68. Hormone therapy to prevent disease and prolong life in postmenopausal women
69. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women
70. The protective effects of estrogen on the cardiovascular system
71. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
72. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
73. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study
74. Design of the Women's Health Initiative clinical trial and observational study
75. Design and Methods of the Raloxifene Use for the Heart (RUTH) Study
76. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect
77. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial
78. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
79. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial
80. Estimated prevalence of Alzheimer's disease in the United States
81. Comparative distribution of estrogen receptor-alpha and - Beta mRNA in the rat central nervous system
82. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain
83. Estrogen increases the density of 5-hydroxytryptamine (2A) receptors in cerebral cortex and nucleus accumbens in the female rat
84. Oestrogen effects on dopaminergic function in striatum
85. Oestrogen modulation of noradrenaline neurotransmission
86. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women
87. Estrogen use and verbal memory in healthy postmenopausal women
88. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women
89. Estrogen replacement therapy and cognitive function in older women
90. Oestrogen therapy and the menopausal syndrome
91. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women
92. Effects of estrogen on memory function in surgically menopausal women
93. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females
94. Effect of short-term transdermal estrogen replacement therapy on sleep: A randomized, double-blind crossover trial in postmenopausal women
95. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?
96. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
97. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia
98. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
99. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. Alzheimer's disease Cooperative Study
100. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen
101. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents
102. The effects of tamoxifen and estrogen on brain metabolism in elderly women
103. Raloxifene hydrochloride, a selective estrogen receptor modulator: Safety assessment of effects on cognitive function and mood in postmenopausal women
104. Cognitive function in postmenopausal women treated with raloxifene
105. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age
106. Affective symptoms in women attending a menopause clinic
107. Hormonal characteristics of the human menstrual cycle throughout reproductive life
108. Objective techniques for the assessment of postmenopausal hot flashes
109. Compliance with hormone replacement therapy in postmenopausal women. A comparative study
110. Enhancing patient compliance with hormone replacement therapy at menopause
111. Compliance difficulties with progestin-supplemented estrogen replacement therapy
112. Estrogen replacement therapy: Determinants of persistence with treatment
113. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
114. Chemoprevention of breast cancer: The Italian experience
115. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial
116. The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and new perspectives
117. Hormone replacement therapy in breast cancer survivors
118. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: Hormone replacement therapy and breast cancer
119. Estrogen replacement therapy for breast cancer patients
120. Symptoms associated with tamoxifen treatment in postmenopausal women
121. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study
122. Adverse events reported by postmenopausal women in controlled trials with raloxifene
123. The effect of tamoxifen on the endometrium
124. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
125. Low-potency oestrogen and risk of endometrial cancer: A case-control study
126. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
127. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
128. Oral contraceptives and venous thromboembolism: Findings in a large prospective study
129. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
130. Risk of venous thromboembolism in users of hormone replacement therapy
131. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
132. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
133. Prospective study of exogenous hormones and risk of pulmonary embolism in women
134. A clinical trial of estrogen-replacement therapy after ischemic stroke
135. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
136. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
137. Estrogen receptor beta in breast cancer
138. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer